Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
7 "Ji Hyung Hong"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Breast cancer
Real-World Clinical Data of Palbociclib in Asian Metastatic Breast Cancer Patients: Experiences from Eight Institutions
Jieun Lee, Hyung Soon Park, Hye Sung Won, Ji Hyun Yang, Hee Yeon Lee, In Sook Woo, Kabsoo Shin, Ji Hyung Hong, Young Joon Yang, Sang Hoon Chun, Jae Ho Byun
Cancer Res Treat. 2021;53(2):409-423.   Published online October 28, 2020
DOI: https://doi.org/10.4143/crt.2020.451
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Use of cyclin-dependent kinase 4/6 inhibitors improved survival outcome of hormone receptor (HR) positive metastatic breast cancer (MBC) patients, including Asian population. However, Asian real-world data of palbociclib is limited. We analyzed the real-world clinical practice patterns and outcome in HR-positive, MBC Asian patients treated with palbociclib.
Materials and Methods
Between April 2017 to November 2019, 169 HR-positive, human epidermal growth factor-2–negative MBC patients treated with letrozole or fulvestrant plus palbocilib were enrolled from eight institutions. Survival outcome (progression-free survival [PFS]), treatment response and toxicity profiles were analyzed.
Results
Median age of letrozole plus palbociclib (145 patients, 85.8%) and fulvestrant plus palbociclib (24 patients, 14.2%) was 58 and 53.5 years, with median follow-up duration of 14.63 months (range 0.2 to 33.9 months). Median PFS (mPFS) of letrozole plus palbociclib and fulvestrant plus palbociclib was 25.6 (95% confidence interval [CI], 19.1 to not reached) and 6.37 months (95% CI, 5.33 to not reached), comparable to previous phase 3 trials. In letrozole plus palbociclib arm, luminal A (hazard ratio, 2.86; 95% CI, 1.20 to 6.80; p=0.017) and patients with good performance (Eastern Cooperative Oncology Group 0-1 [hazard ratio, 3.68; 95% CI, 1.70 to 7.96]) showed better mPFS. In fulvestrant plus palbociclib group, chemotherapy naïve patients showed better mPFS (hazard ratio, 12.51, 95% CI, 1.59 to 99.17; p=0.017). The most common grade 3 or 4 adverse event was neutropenia (letrozole 86.3%, fulvestrant 88.3%).
Conclusion
To our knowledge, this is the first real-world data of palbociclib reported in Asia. Palbociclib showed comparable benefit to previous phase 3 trials in Asian patients during daily clinical practice.

Citations

Citations to this article as recorded by  
  • Efficacy and Safety of Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials and Real-World Studies
    Hui-Chen Su, Ho-Wei Lin, Ka-Wai Tam
    Targeted Oncology.2025; 20(1): 71.     CrossRef
  • Palbociclib in Older Patients with Advanced/Metastatic Breast Cancer: A Systematic Review
    Etienne Brain, Connie Chen, Sofia Simon, Vinay Pasupuleti, Kathleen Vieira Pfitzer, Karen A. Gelmon
    Targeted Oncology.2024; 19(3): 303.     CrossRef
  • Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-l
    Tetsuhiro Yoshinami, Shigenori E. Nagai, Masaya Hattori, Takuho Okamura, Kenichi Watanabe, Takahiro Nakayama, Hiroko Masuda, Michiko Tsuneizumi, Daisuke Takabatake, Michiko Harao, Hiroshi Yoshino, Natsuko Mori, Hiroyuki Yasojima, Chiya Oshiro, Madoka Iwas
    Breast Cancer.2024; 31(4): 621.     CrossRef
  • The Effect of C-Reactive Protein/Lymphocyte Ratio (CLR) on PFS in Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors: A Novel Biomarker
    Mehmet Buyukbayram, Zekeriya Hannarici, Yakup Duzkopru, Aykut Turhan, Alperen Caglar, Pınar Coban Esdur, Mehmet Bilici, Salim Tekin, Doğan Yazılıtaş
    Breast Cancer: Targets and Therapy.2024; Volume 16: 329.     CrossRef
  • The treatment pattern of advanced HR-positive and HER2-negative breast cancer in central southern China: a hospital-based cross-sectional study
    Zhe-Yu Hu, Binliang Liu, Ning Xie, Xiaohong Yang, Liping Liu, Huawu Xiao, Jing Li, Hui Wu, Jianxiang Gao, Jun Lu, Xuming Hu, Min Cao, Zhengrong Shui, Can Tian, Quchang Ouyang
    BMC Cancer.2024;[Epub]     CrossRef
  • Palbociclib in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer: A Systematic Scoping Review of Real-World Evidence from Countries Outside of Western Regions that Are Underrepresented in Clinical Trials
    Amit Rauthan, Ankita Jain, Manmohan Singh, Mehmet A. N. Sendur
    Oncology and Therapy.2024; 12(3): 395.     CrossRef
  • Real-world comparison of palbociclib, abemaciclib, and dalpiciclib as first-line treatments for Chinese HR+/HER2−metastatic breast cancer patients: a multicenter study (YOUNGBC-28)
    Yifan Chen, Yizhao Xie, Die Sang, Ning Xie, Xinhua Han, Yanxia Zhao, Juanjuan Li, Jian Yue, Peng Yuan, Biyun Wang
    Therapeutic Advances in Medical Oncology.2024;[Epub]     CrossRef
  • Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China
    Jiao Yang, Bing Zhao, Xiaoling Ling, Donghui Li, Jiuda Zhao, Yonggang Lv, Guangxi Wang, Xinlan Liu, Nanlin Li, Jin Yang
    BMC Cancer.2023;[Epub]     CrossRef
  • A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance® Patient Program
    Carlo Palmieri, Alison Musson, Catherine Harper-Wynne, Duncan Wheatley, Gianfilippo Bertelli, Iain R. Macpherson, Mark Nathan, Ellie McDowall, Ajay Bhojwani, Mark Verrill, Joe Eva, Colm Doody, Ruhe Chowdhury
    British Journal of Cancer.2023; 129(5): 852.     CrossRef
  • Real-world effectiveness of palbociclib plus fulvestrant in advanced breast cancer: Results from a population-based cohort study
    Fábio Cardoso Borges, Filipa Alves da Costa, Adriana Ramos, Catarina Ramos, Catarina Bernardo, Cláudia Brito, Alexandra Mayer-da-Silva, Cláudia Furtado, Arlindo R. Ferreira, Diogo Martins-Branco, Ana Miranda, António Lourenço
    The Breast.2022; 62: 135.     CrossRef
  • The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer
    Fulbert Fu, Jessica Kano, Julia Ma, Mera Guindy
    Current Oncology.2022; 29(3): 1761.     CrossRef
  • Treatment patterns, effectiveness, and patient‐reported outcomes of palbociclib therapy in Chinese patients with advanced breast cancer: A multicenter ambispective real‐world study
    Lesang Shen, Jun Zhou, Yiding Chen, Jinhua Ding, Haiyan Wei, Jian Liu, Wenjie Xia, Bojian Xie, Xiaohong Xie, Xujun Li, Yuechu Dai, Guobing Zhang, Xia Qiu, Chao Li, Shanshan Sun, Wuzhen Chen, Dihe Gong, Hengyu Li, Jian Huang, Xia Jiang, Chao Ni
    Cancer Medicine.2022; 11(22): 4157.     CrossRef
  • Starting dose selection of palbociclib in Chinese patients with breast cancer based on population kinetic–pharmacodynamic model of neutropenia
    Weizhe Jian, Junsheng Xue, Qingyu Yao, Rong Chen, Ye Yao, Mopei Wang, Tianyan Zhou
    Cancer Chemotherapy and Pharmacology.2022; 90(6): 489.     CrossRef
  • Early Application of Palbociclib Plus Endocrine Therapy in HR+/HER2− Metastatic Breast Cancer: A Better Choice Based on Data From the Chinese Population
    Yusi Zhang, Wenlin Chen, Shuanglong Chen, Qingmo Yang, Zhong Ouyang
    Technology in Cancer Research & Treatment.2022;[Epub]     CrossRef
  • Real-world Treatment Patterns and Clinical Outcomes Associated With Palbociclib Combination Therapy: A Multinational, Pooled Analysis From the Ibrance Real World Insights Study
    Katie Mycock, Kent A. Hanson, Gavin Taylor-Stokes, Gary Milligan, Christian Atkinson, Debanjali Mitra, Salena Preciado, Ernest H. Law
    Clinical Therapeutics.2022; 44(12): 1588.     CrossRef
  • Multicentric real world evidence with palbociclib in hormone positive HER2 negative metastatic breast cancer in Indian population
    Chaturbhuj Agrawal, Pankaj Goyal, Amit Agarwal, Rupal Tripathi, Chandragouda Dodagoudar, Saphalta Baghmar, Archana Sharma, Ullas Batra, Vineet Talwar, Sumit Goyal, Rajeev Kumar, Dinesh Chandra Doval
    Scientific Reports.2021;[Epub]     CrossRef
  • Which Clinicopathologic Parameters Suggest Primary Resistance to Palbociclib in Combination With Letrozole as the First-Line Treatment for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer?
    Ji-Yeon Kim, Jung Min Oh, Yeon Hee Park, Jin Seok Ahn, Young-Hyuck Im
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • 9,939 View
  • 380 Download
  • 19 Web of Science
  • 17 Crossref
Close layer
Clinical Characteristics of Clear Cell Ovarian Cancer: A Retrospective Multicenter Experience of 308 Patients in South Korea
Hee Yeon Lee, Ji Hyung Hong, Jae Ho Byun, Hee-Jun Kim, Sun Kyung Baek, Jin Young Kim, Ki Hyang Kim, Jina Yun, Jung A Kim, Kwonoh Park, Hyo Jin Lee, Jung Lim Lee, Young-Woong Won, Il Hwan Kim, Woo Kyun Bae, Kyong Hwa Park, Der-Sheng Sun, Suee Lee, Min-Young Lee, Guk Jin Lee, Sook Hee Hong, Yun Hwa Jung, Ho Jung An
Cancer Res Treat. 2020;52(1):277-283.   Published online July 12, 2019
DOI: https://doi.org/10.4143/crt.2019.292
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to evaluate clinical characteristics and treatment pattern of ovarian clear cell carcinoma (OCCC) in Korea and the role of adjuvant chemotherapy in early stage.
Materials and Methods
Medical records of 308 cases of from 21 institutions were reviewed and data including age, performance status, endometriosis, thromboembolism, stage, cancer antigen 125, treatment, recurrence, and death were collected.
Results
Regarding stage of OCCC, it was stage I in 194 (63.6%), stage II in 34 (11.1%), stage III in 66 (21.6%), and stage IV in 11 (3.6%) patients. All patients underwent surgery. Optimal surgery (residual disease ≤ 1 cm) was achieved in 89.3%. Majority of patients (80.5%) received postoperative chemotherapy. The most common regimen was taxane-platinum combination (96%). Median relapse-free survival (RFS) was 138.5 months for stage I, 33.4 for stage II, 19.3 for stage III, and 9.7 for stage IV. Median overall survival (OS) were not reached, 112.4, 48.7, and 18.3 months for stage I, II, III, and IV, respectively. Early-stage (stage I), endometriosis, and optimal debulking were identified as favorable prognostic factors for RFS. Early-stage and optimal debulking were also favorable prognostic factors for OS. Majority of patients with early-stage received adjuvant chemotherapy. However, additional survival benefit was not found in terms of recurrence.
Conclusion
Majority of patients had early-stage and received postoperative chemotherapy regardless of stage. Early-stage and optimal debulking were identified as favorable prognostic factors. In stage IA or IB, adding adjuvant chemotherapy did not show difference in survival. Further study focusing on OCCC is required.

Citations

Citations to this article as recorded by  
  • Ovarian clear cell carcinoma: open questions on the management and treatment algorithm
    Roberta Rosso, Margherita Turinetto, Fulvio Borella, Nicolas Chopin, Pierre Meeus, Alexandra Lainè, Isabelle Ray-Coquard, Olivia Le Saux, Domenico Ferraioli
    The Oncologist.2025;[Epub]     CrossRef
  • From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer
    Zesi Liu, Chunli Jing, Fandou Kong
    Journal of Ovarian Research.2024;[Epub]     CrossRef
  • SOX17 expression in ovarian clear cell carcinoma
    Daichi Kodama, Motoki Takenaka, Chiemi Saigo, Masako Azuma, Yuki Hanamatsu, Masanori Isobe, Tamotsu Takeuchi
    Journal of Ovarian Research.2024;[Epub]     CrossRef
  • Construction of a Prediction Model of Cancer-Specific Survival after Ovarian Clear Cell Carcinoma Surgery
    Mengqi Huang, Li Ling, Yanbo Liu, Yujuan Li
    Clinical and Experimental Obstetrics & Gynecology.2024;[Epub]     CrossRef
  • Patients with stage IA ovarian clear cell carcinoma do not require chemotherapy following surgery
    Li Shuqing, Zhu Zhiling
    Cancer Medicine.2023; 12(6): 6668.     CrossRef
  • Clear cell carcinoma of the ovary and venous thromboembolism: a systematic review and meta-analysis
    Hamidreza Didar, Farah Farzaneh, Hanieh Najafiarab, Kosar Namakin, Kimiya Gohari, Ali Sheidaei, Sepehr Ramezani
    Current Medical Research and Opinion.2023; 39(6): 901.     CrossRef
  • The Significance of Radiotherapy in Ovarian Clear Cell Carcinoma: A Systematic Review and Meta-Analysis
    Yuan Zhuang, Hua Yang
    Cancer Control.2023;[Epub]     CrossRef
  • Clinical perspectives of rare ovarian tumors: clear cell ovarian cancer
    Satoe Fujiwara
    Japanese Journal of Clinical Oncology.2023; 53(8): 664.     CrossRef
  • Application of precision medicine based on next-generation sequencing and immunohistochemistry in ovarian cancer: a real-world experience
    Yoo-Na Kim, Yun Soo Chung, Ji Hyun Lee, Eunhyang Park, Seung-Tae Lee, Sunghoon Kim, Jung-Yun Lee
    Journal of Gynecologic Oncology.2023;[Epub]     CrossRef
  • Characteristics and Prognosis of Ovarian Pure Clear Cell Carcinoma: A Retrospective Experience of 136 Patients
    Yang Gao, Wei Ding, Pengpeng Qu
    Clinical and Experimental Obstetrics & Gynecology.2023;[Epub]     CrossRef
  • A clearer view on ovarian clear cell carcinoma
    Aglaja De Pauw, Eline Naert, Koen Van de Vijver, Tummers Philippe, Katrien Vandecasteele, Hannelore Denys
    Acta Clinica Belgica.2022; 77(4): 792.     CrossRef
  • Friend or foe? The prognostic role of endometriosis in women with clear cell ovarian carcinoma. A UK population-based cohort study
    Anastasios Tranoulis, Felicia Helena Buruiana, Bindiya Gupta, Audrey Kwong, Aarti Lakhiani, Jason Yap, Janos Balega, Kavita Singh
    Archives of Gynecology and Obstetrics.2022; 305(5): 1279.     CrossRef
  • Association Between Endometriosis and Prognosis of Ovarian Cancer: An Updated Meta-Analysis
    Peng Chen, Chi-Yuan Zhang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Clinical analysis and literature review of a case of ovarian clear cell carcinoma with PIK3CA gene mutation: A case report
    Abdulkarim Mohamed Farah, Shiyu Gu, Yan Jia
    Medicine.2022; 101(37): e30666.     CrossRef
  • Clear cell carcinoma of the ovary: a clinical and molecular perspective
    Yasushi Iida, Aikou Okamoto, Robert L Hollis, Charlie Gourley, C Simon Herrington
    International Journal of Gynecological Cancer.2021; 31(4): 605.     CrossRef
  • Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study
    Chenchen Zhu, Jing Zhu, Lili Qian, Hanyuan Liu, Zhen Shen, Dabao Wu, Weidong Zhao, Weihua Xiao, Ying Zhou
    BMC Cancer.2021;[Epub]     CrossRef
  • The oncological outcome of the patients with ovarian clear cell cancer: Platinum-based adjuvant chemotherapy is not suitable
    Caner ÇAKIR, Fatih KILIÇ, Çiğdem KILIÇ, Dilek YÜKSEL, Vakkas KORKMAZ, Günsu KİMYON CÖMERT, Osman TÜRKMEN, Taner TURAN
    Journal of Surgery and Medicine.2021; 5(8): 1.     CrossRef
  • Development and validation of Nomograms for predicting overall survival and Cancer-specific survival in patients with ovarian clear cell carcinoma
    Qian Chen, Shu Wang, Jing-He Lang
    Journal of Ovarian Research.2020;[Epub]     CrossRef
  • 8,989 View
  • 421 Download
  • 22 Web of Science
  • 18 Crossref
Close layer
Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma
Sun Min Lim, Sang Hee Cho, In Gyu Hwang, Jae Woo Choi, Hyun Chang, Myung-Ju Ahn, Keon Uk Park, Ji-Won Kim, Yoon Ho Ko, Hee Kyung Ahn, Byoung Chul Cho, Byung-Ho Nam, Sang Hoon Chun, Ji Hyung Hong, Jung Hye Kwon, Jong Gwon Choi, Eun Joo Kang, Tak Yun, Keun-Wook Lee, Joo-Hang Kim, Jin Soo Kim, Hyun Woo Lee, Min Kyoung Kim, Dongmin Jung, Ji Eun Kim, Bhumsuk Keam, Hwan Jung Yun, Sangwoo Kim, Hye Ryun Kim
Cancer Res Treat. 2019;51(1):300-312.   Published online May 9, 2018
DOI: https://doi.org/10.4143/crt.2018.012
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Head and neck squamous cell carcinoma (HNSCC) is a deadly disease in which precision medicine needs to be incorporated. We aimed to implement next-generation sequencing (NGS) in determining actionable targets to guide appropriate molecular targeted therapy in HNSCC patients.
Materials and Methods
Ninety-three tumors and matched blood samples underwent targeted sequencing of 244 genes using the Illumina HiSeq 2500 platform with an average depth of coverage of greater than 1,000×. Clinicopathological data from patients were obtained from 17 centers in Korea, and were analyzed in correlation with NGS data.
Results
Ninety-two of the 93 tumors were amenable to data analysis. TP53 was the most common mutation, occurring in 47 (51%) patients, followed by CDKN2A (n=23, 25%), CCND1 (n=22, 24%), and PIK3CA (n=19, 21%). The total mutational burden was similar between human papillomavirus (HPV)–negative vs. positive tumors, although TP53, CDKN2A and CCND1 gene alterations occurred more frequently in HPV-negative tumors. HPV-positive tumors were significantly associated with immune signature-related genes compared to HPV-negative tumors. Mutations of NOTCH1 (p=0.027), CDKN2A (p < 0.001), and TP53 (p=0.038) were significantly associated with poorer overall survival. FAT1 mutations were highly enriched in cisplatin responders, and potentially targetable alterations such as PIK3CA E545K and CDKN2A R58X were noted in 14 patients (15%).
Conclusion
We found several targetable genetic alterations, and our findings suggest that implementation of precision medicine in HNSCC is feasible. The predictive value of each targetable alteration should be assessed in a future umbrella trial using matched molecular targeted agents.

Citations

Citations to this article as recorded by  
  • Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial
    Bhumsuk Keam, Min Hee Hong, Seong Hoon Shin, Seong Gu Heo, Ji Eun Kim, Hee Kyung Ahn, Yun-Gyoo Lee, Keon-Uk Park, Tak Yun, Keun-Wook Lee, Sung-Bae Kim, Sang-Cheol Lee, Min Kyoung Kim, Sang Hee Cho, So Yeon Oh, Sang-Gon Park, Shinwon Hwang, Byung-Ho Nam, S
    Journal of Clinical Oncology.2024; 42(5): 507.     CrossRef
  • A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma: In-Depth Analysis of Nintedanib Arm from the KCSG HN 15-16 TRIUMPH Trial
    Kyoo Hyun Kim, Sun Min Lim, Hee Kyung Ahn, Yun-Gyoo Lee, Keun-Wook Lee, Myung-Ju Ahn, Bhumsuk Keam, Hye Ryun Kim, Hyun Woo Lee, Ho Jung An, Jin-Soo Kim
    Cancer Research and Treatment.2024; 56(1): 37.     CrossRef
  • Extracellular vesicles as tools and targets in therapy for diseases
    Mudasir A. Kumar, Sadaf K. Baba, Hana Q. Sadida, Sara Al. Marzooqi, Jayakumar Jerobin, Faisal H. Altemani, Naseh Algehainy, Mohammad A. Alanazi, Abdul-Badi Abou-Samra, Rakesh Kumar, Ammira S. Al-Shabeeb Akil, Muzafar A. Macha, Rashid Mir, Ajaz A. Bhat
    Signal Transduction and Targeted Therapy.2024;[Epub]     CrossRef
  • Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study
    Dong Hyun Kim, Seung Taek Lim, Hye Ryun Kim, Eun Joo Kang, Hee Kyung Ahn, Yun-Gyoo Lee, Der Sheng Sun, Jung Hye Kwon, Sang-Cheol Lee, Hyun Woo Lee, Min Kyoung Kim, Bhumsuk Keam, Keon-Uk Park, Seong-Hoon Shin, Hwan Jung Yun
    Oral Oncology.2024; 151: 106739.     CrossRef
  • Characterization of macrophages in head and neck squamous cell carcinoma and development of MRG-based risk signature
    Lei Liu, Qiang Liu
    Scientific Reports.2024;[Epub]     CrossRef
  • The Next Chapter in Cancer Diagnostics: Advances in HPV-Positive Head and Neck Cancer
    Antea Krsek, Lara Baticic, Tamara Braut, Vlatka Sotosek
    Biomolecules.2024; 14(8): 925.     CrossRef
  • Biomarkers in head and neck squamous cell carcinoma: unraveling the path to precision immunotherapy
    Kamal S. Saini, Sasikala Somara, Heidi C. Ko, Purva Thatai, Angela Quintana, Zachary D. Wallen, Michelle F. Green, Ravi Mehrotra, Sandra McGuigan, Lingjuan Pang, Soma Das, Kavita Yadav, Dobrica Neric, Luca Cantini, Chinmayee Joshi, Kazuya Iwamoto, Sudha D
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Massive parallel sequencing of head and neck conventional squamous cell carcinomas: A comprehensive review
    Alfons Nadal, Antonio Cardesa, Abbas Agaimy, Alhadi Almangush, Alessandro Franchi, Henrik Hellquist, Ilmo Leivo, Nina Zidar, Alfio Ferlito
    Virchows Archiv.2024; 485(6): 965.     CrossRef
  • FAT1 expression in T-cell acute lymphoblastic leukemia (T-ALL) modulates proliferation and WNT signaling
    Sven Liebig, Martin Neumann, Patricia Silva, Jutta Ortiz-Tanchez, Veronika Schulze, Konstandina Isaakidis, Cornelia Schlee, Michael P. Schroeder, Thomas Beder, Luc G. T. Morris, Timothy A. Chan, Lorenz Bastian, Thomas Burmeister, Stefan Schwartz, Nicola G
    Scientific Reports.2023;[Epub]     CrossRef
  • Short-term immune-checkpoint inhibition partially rescues perturbed bone marrow hematopoiesis in mismatch-repair deficient tumors
    Paula Krone, Annabell Wolff, Julia Teichmann, Johanna Maennicke, Julia Henne, Leonie Engster, Inken Salewski, Wendy Bergmann, Christian Junghanss, Claudia Maletzki
    OncoImmunology.2023;[Epub]     CrossRef
  • Genetic Mutations Associated with Inflammatory Response Caused by HPV Integration in Oropharyngeal Squamous Cell Carcinoma
    Mai Atique, Isis Muniz, Fatemeh Farshadi, Michael Hier, Alex Mlynarek, Marco Macarella, Mariana Maschietto, Belinda Nicolau, Moulay A. Alaoui-Jamali, Sabrina Daniela da Silva
    Biomedicines.2023; 12(1): 24.     CrossRef
  • New Treatment Development for Larynx Preservation
    Susumu Okano
    Koutou (THE LARYNX JAPAN).2023; 35(2): 98.     CrossRef
  • Current Trends in Precision Medicine and Next-Generation Sequencing in Head and Neck Cancer
    Roberto N. Solis, Dustin A. Silverman, Andrew C. Birkeland
    Current Treatment Options in Oncology.2022; 23(2): 254.     CrossRef
  • EGFR Mutation and 11q13 Amplification Are Potential Predictive Biomarkers for Immunotherapy in Head and Neck Squamous Cell Carcinoma
    Shengjin Dou, Lin Zhang, Chong Wang, Yanli Yao, Wen Jiang, Lulu Ye, Jiang Li, Sicheng Wu, Debin Sun, Xiaoli Gong, Rongrong Li, Guopei Zhu
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • Diagnostics of HNSCC Patients: An Analysis of Cell Lines and Patient-Derived Xenograft Models for Personalized Therapeutical Medicine
    Ramona Gabriela Ursu, Ionut Luchian, Costin Damian, Elena Porumb-Andrese, Nicolae Ghetu, Roxana Gabriela Cobzaru, Catalina Lunca, Carmen Ripa, Diana Costin, Igor Jelihovschi, Florin Dumitru Petrariu, Luminita Smaranda Iancu
    Diagnostics.2022; 12(5): 1071.     CrossRef
  • Unraveling most abundant mutational signatures in head and neck cancer
    Michaela Plath, Johanna Gass, Mario Hlevnjak, Qiaoli Li, Bohai Feng, Xavier Pastor Hostench, Matthias Bieg, Lea Schroeder, Dana Holzinger, Marc Zapatka, Kolja Freier, Wilko Weichert, Jochen Hess, Karim Zaoui
    International Journal of Cancer.2021; 148(1): 115.     CrossRef
  • Worldwide prevalence of PI3K-AKT-mTOR pathway mutations in head and neck cancer: A systematic review and meta-analysis
    Adriana Castelo de Moura, Daniele Xavier Assad, Juliana Amorim dos Santos, Isabela Porto de Toledo, Gustavo Barcelos Barra, Rogerio Moraes Castilho, Cristiane Helena Squarize, Eliete Neves Silva Guerra
    Critical Reviews in Oncology/Hematology.2021; 160: 103284.     CrossRef
  • Immuno-Oncological Biomarkers for Squamous Cell Cancer of the Head and Neck: Current State of the Art and Future Perspectives
    Stijn J. De Keukeleire, Tijl Vermassen, Elien Hilgert, David Creytens, Liesbeth Ferdinande, Sylvie Rottey
    Cancers.2021; 13(7): 1714.     CrossRef
  • Comprehensive Analysis of Mutation-Based and Expressed Genes-Based Pathways in Head and Neck Squamous Cell Carcinoma
    Bhumsuk Keam, Jin-Young Park, Jin-Pyo Kim, Gun-Do Kim, Yun-Suk Yu, Sang-Hee Cho, Sangwoo Kim, Hee-Kyung Ahn, Sang-Hoon Chun, Jung-Hye Kwon, Tak Yun, Ji-Won Kim, Ji-Eun Kim, Myung-Ju Ahn, Joo-Hang Kim, Hwan-Jung Yun
    Processes.2021; 9(5): 792.     CrossRef
  • Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma
    Teresa Magnes, Sandro Wagner, Dominik Kiem, Lukas Weiss, Gabriel Rinnerthaler, Richard Greil, Thomas Melchardt
    International Journal of Molecular Sciences.2021; 22(9): 4981.     CrossRef
  • A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
    Ji Hyun Lee, Seong Gu Heo, Beung‐Chul Ahn, Min Hee Hong, Byoung Chul Cho, Sun Min Lim, Hye Ryun Kim
    Cancer Medicine.2021; 10(20): 7012.     CrossRef
  • Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma
    Nan Jin, Bhumsuk Keam, Janice Cho, Michelle J. Lee, Hye Ryun Kim, Hayarpi Torosyan, Natalia Jura, Patrick K.S. Ng, Gordon B. Mills, Hua Li, Yan Zeng, Zohar Barbash, Gabi Tarcic, Hyunseok Kang, Julie E. Bauman, Mi-Ok Kim, Nathan K. VanLandingham, Danielle
    Journal of Clinical Investigation.2021;[Epub]     CrossRef
  • Understanding the Pattern of Oropharyngeal Cancers from North-East Romanian Patients
    Ramona Ursu, Simona Giusca, Irene Spiridon, Bianca Manole, Mihai Danciu, Victor Costan, Dragos Palade, Nicolae Ghetu, Paula Toader, Mădălina Vlad, Costin Damian, Elena Porumb-Andrese, Ionut Luchian, Luminița Iancu
    Applied Sciences.2021; 11(24): 12079.     CrossRef
  • Immunologic and immunogenomic aspects of tumor progression
    Andrea Ladányi, József Tímár
    Seminars in Cancer Biology.2020; 60: 249.     CrossRef
  • Prospective assessment of the clinical benefit of a tailored cancer gene set built on a next-generation sequencing platform in patients with recurrent or metastatic head and neck cancer
    Thomas C. Westbrook, Ian S. Hagemann, Jessica Ley, Kevin Chen, Kevin Palka, Jingxia Liu, Ling Chen, Peter Oppelt, Douglas Adkins
    Medical Oncology.2020;[Epub]     CrossRef
  • Biological Determinants of Chemo-Radiotherapy Response in HPV-Negative Head and Neck Cancer: A Multicentric External Validation
    Martijn van der Heijden, Paul B. M. Essers, Monique C. de Jong, Reinout H. de Roest, Sebastian Sanduleanu, Caroline V. M. Verhagen, Olga Hamming-Vrieze, Frank Hoebers, Philippe Lambin, Harry Bartelink, C. René Leemans, Marcel Verheij, Ruud H. Brakenhoff,
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response
    Min Hwan Kim, Jae-Hwan Kim, Ji Min Lee, Jae Woo Choi, Dongmin Jung, Hojin Cho, Hyundeok Kang, Min Hee Hong, Su Jin Heo, Se Heon Kim, Eun Chang Choi, Da Hee Kim, Young Min Park, Sangwoo Kim, Sun Och Yoon, Yoon Woo Koh, Byoung Chul Cho, Hye Ryun Kim
    British Journal of Cancer.2020; 122(11): 1649.     CrossRef
  • Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer
    Han Na Kang, Jae-Hwan Kim, A-Young Park, Jae Woo Choi, Sun Min Lim, Jinna Kim, Eun Joo Shin, Min Hee Hong, Kyoung-Ho Pyo, Mi Ran Yun, Dong Hwi Kim, Hanna Lee, Sun Och Yoon, Da Hee Kim, Young Min Park, Hyung Kwon Byeon, Inkyung Jung, Soonmyung Paik, Yoon W
    BMC Cancer.2020;[Epub]     CrossRef
  • Impact of genetic variants in clinical outcome of a cohort of patients with oropharyngeal squamous cell carcinoma
    Ana Carolina de Carvalho, Sandra Perdomo, Wellington dos Santos, Gabriela Carvalho Fernandes, Lais Machado de Jesus, Raiany Santos Carvalho, Cristovam Scapulatempo-Neto, Gisele Caravina de Almeida, Bruna Pereira Sorroche, Lidia Maria Rebolho Batista Arant
    Scientific Reports.2020;[Epub]     CrossRef
  • Prognostic Value of CD200R1 mRNA Expression in Head and Neck Squamous Cell Carcinoma
    Hyun Chang, Yun-Gyoo Lee, Yoon Ho Ko, Jang Ho Cho, Jong-Kwon Choi, Keon Uk Park, Eun Joo Kang, Keun-Wook Lee, Sun Min Lim, Jin-Soo Kim, Hyun Woo Lee, Min Kyoung Kim, In Gyu Hwang, Sangwoo Kim, Byung-Ho Nam, Hye Ryun Kim
    Cancers.2020; 12(7): 1777.     CrossRef
  • Mouse–human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck
    Hye Ryun Kim, Han Na Kang, Mi Ran Yun, Kwon Young Ju, Jae Woo Choi, Dong Min Jung, Kyoung Ho Pyo, Min Hee Hong, Myoung-Ju Ahn, Jong-Mu Sun, Han Sang Kim, Jinna Kim, Jinseon Yoo, Kyu Ryung Kim, Yoon Woo Koh, Se Heon Kim, Eun Chang Choi, Sun Ock Yoon, Hyo S
    British Journal of Cancer.2020; 123(12): 1720.     CrossRef
  • Mutationssignaturen beim Kopf- und Hals-Tumor
    M. Plath, J. Hess, K. Zaoui
    HNO.2020; 68(12): 922.     CrossRef
  • BAMixChecker: an automated checkup tool for matched sample pairs in NGS cohort
    Hein Chun, Sangwoo Kim, Inanc Birol
    Bioinformatics.2019; 35(22): 4806.     CrossRef
  • Diagnostic Tumor Markers in Head and Neck Squamous Cell Carcinoma (HNSCC) in the Clinical Setting
    Panagiota Economopoulou, Remco de Bree, Ioannis Kotsantis, Amanda Psyrri
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • A Review of HPV-Related Head and Neck Cancer
    Kazuhiro Kobayashi, Kenji Hisamatsu, Natsuko Suzui, Akira Hara, Hiroyuki Tomita, Tatsuhiko Miyazaki
    Journal of Clinical Medicine.2018; 7(9): 241.     CrossRef
  • 15,289 View
  • 650 Download
  • 35 Web of Science
  • 35 Crossref
Close layer
Clinical Features of Male Breast Cancer: Experiences from Seven Institutions Over 20 Years
Ji Hyung Hong, Kyung Sun Ha, Yun Hwa Jung, Hye Sung Won, Ho Jung An, Guk Jin Lee, Donghoon Kang, Ji Chan Park, Sarah Park, Jae Ho Byun, Young Jin Suh, Jeong Soo Kim, Woo Chan Park, Sang Seol Jung, Il Young Park, Su-Mi Chung, In Sook Woo
Cancer Res Treat. 2016;48(4):1389-1398.   Published online April 11, 2016
DOI: https://doi.org/10.4143/crt.2015.410
AbstractAbstract PDFPubReaderePub
Purpose
Breast cancer treatment has progressed significantly over the past 20 years. However, knowledge regarding male breast cancer (MBC) is sparse because of its rarity. This study is an investigation of the clinicopathologic features, treatments, and clinical outcomes of MBC.
Materials and Methods
Clinical records of 59 MBC patients diagnosed during 1995-2014 from seven institutions in Korea were reviewed retrospectively.
Results
Over a 20-year period, MBC patients accounted for 0.98% among total breast cancer patients, and increased every 5 years. The median age of MBC patientswas 66 years (range, 24 to 87 years). Forty-three patients (73%) complained of a palpable breast mass initially. The median symptom duration was 5 months (range, 1 to 36 months). Mastectomy was performed in 96% of the patients. The most frequent histology was infiltrating ductal carcinoma (75%). Ninety-one percent of tumors (38/43) were estrogen receptor–positive, and 28% (11/40) showed epidermal growth factor receptor 2 (HER-2) overexpression. After curative surgery, 42% of patients (19/45) received adjuvant chemotherapy; 77% (27/35) received hormone therapy. Five out of ten patients with HER-2 overexpressing tumors did not receive adjuvant anti–HER-2 therapy, while two out of four patients with HER-2 overexpressing tumors received palliative trastuzumab for recurrent and metastatic disease. Letrozole was used for one patient in the palliative setting. The median overall survival durations were 7.2 years (range, 0.6 to 17.0 years) in patients with localized disease and 2.9 years (range, 0.6 to 4.3 years) in those with recurrent or metastatic disease.
Conclusion
Anti–HER-2 and hormonal therapy, except tamoxifen, have been underutilized in Korean MBC patients compared to female breast cancer patients. With the development of precision medicine, active treatment with targeted agents should be applied. Further investigation of the unique pathobiology of MBC is clinically warranted.

Citations

Citations to this article as recorded by  
  • Cost-effectiveness of adjuvant endocrine treatment with tamoxifen for male breast cancer
    Yaping Huang, Chengjie Ke, Jiaqin Cai, Xiaoxia Wei, Maohua Chen, Hong Sun
    Breast Cancer.2024; 31(5): 917.     CrossRef
  • Cáncer de mama en el varón: estudio multicéntrico en Aragón durante 27 años
    Olga Dobato Portoles, Daniel Aparicio Lopez, Reyes Ibañez Carreras, Elena Aguirre Ortega, Beatriz Eizaguirre Zarza, Carmen García Mur, Aurora Carrasquer Puyal, María Pilar Cebollero Benito, Laura Isabel Comín Novella, Marta Allue Cabañuz, Fernando Martine
    Cirugía Española.2024; 102(10): 524.     CrossRef
  • Observational Study of Men and Women with Breast Cancer in Terms of Overall Survival
    Vlad Bogdan Varzaru, Diana-Maria Anastasiu-Popov, Anca-Elena Eftenoiu, Roxana Popescu, Daliborca Cristina Vlad, Cristian Sebastian Vlad, Aurica Elisabeta Moatar, Daniela Puscasiu, Ionut Marcel Cobec
    Cancers.2024; 16(17): 3049.     CrossRef
  • Male breast cancer: A multicenter study in Aragon over 27 years
    Olga Dobato Portoles, Daniel Aparicio Lopez, Reyes Ibañez Carreras, Elena Aguirre Ortega, Beatriz Eizaguirre Zarza, Carmen García Mur, Aurora Carrasquer Puyal, María Pilar Cebollero Benito, Laura Isabel Comín Novella, Marta Allue Cabañuz, Fernando Martine
    Cirugía Española (English Edition).2024; 102(10): 524.     CrossRef
  • Male breast cancer: a 32-year retrospective analysis in radiation therapy referral center in northern Iran
    Mahboobeh Asgharian, Dariush Moslemi, Hossein-Ali Nikbakht, Mohammad-Ali Jahani, Ali Bijani, Hakimeh Mehdizadeh
    Annals of Medicine & Surgery.2024; 86(10): 5756.     CrossRef
  • Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09)
    Jieun Lee, Keun Seok Lee, Sung Hoon Sim, Heejung Chae, Joohyuk Sohn, Gun Min Kim, Kyung-Hee Lee, Su Hwan Kang, Kyung Hae Jung, Jae-ho Jeong, Jae Ho Byun, Su-Jin Koh, Kyoung Eun Lee, Seungtaek Lim, Hee Jun Kim, Hye Sung Won, Hyung Soon Park, Guk Jin Lee, S
    Cancer Research and Treatment.2023; 55(1): 123.     CrossRef
  • Clinicopathological features and correlation analysis of male breast cancer
    Lei Xi, Jinxing Zhou, Yan Wu, Rong Rong
    Medicine.2023; 102(30): e34408.     CrossRef
  • Characteristics of metastasis and survival between male and female breast cancer with different molecular subtypes: A population‐based observational study
    Wentong Fang, Yue Huang, Xu Han, Jinghui Peng, Mingjie Zheng
    Cancer Medicine.2022; 11(3): 764.     CrossRef
  • Comparison of short-term surgical outcomes between men and women with breast cancer: a retrospective study using nationwide inpatient data in Japan
    Takaaki Konishi, Michimasa Fujiogi, Nobuaki Michihata, Kojiro Morita, Hiroki Matsui, Kiyohide Fushimi, Masahiko Tanabe, Yasuyuki Seto, Hideo Yasunaga
    Breast Cancer Research and Treatment.2021; 186(3): 731.     CrossRef
  • Ulcerated Nipple Nodule, Clinicopathologic Challenge: Answer
    Ahmad Adel, Mona R. E. Abdel-Halim, Yosra Abdel-Galeil
    The American Journal of Dermatopathology.2021; 43(6): 466.     CrossRef
  • Genetic Landscape of Male Breast Cancer
    Fernando Augusto Batista Campos, Etienne Rouleau, Giovana Tardin Torrezan, Dirce Maria Carraro, José Claudio Casali da Rocha, Higor Kassouf Mantovani, Leonardo Roberto da Silva, Cynthia Aparecida Bueno de Toledo Osório, Solange Moraes Sanches, Sandrine M.
    Cancers.2021; 13(14): 3535.     CrossRef
  • Treatment of male breast cancer: meta-analysis of real-world evidence
    A. P. Lin, T.-W. Huang, K.-W. Tam
    British Journal of Surgery.2021; 108(9): 1034.     CrossRef
  • Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells
    Ana D. Pinzón-García, Ruben Sinisterra, Maria Cortes, Fredy Mesa, Sandra Ramírez-Clavijo
    PeerJ.2021; 9: e12124.     CrossRef
  • Prognostic Factors in Male Breast Cancer: A Retrospective Nationwide Study in South Korea by the Study of SMARTSHIP Group
    Sungmin Park, Ho Hur, Ji Sung Lee, JaeSun Yoon, Sung Mo Hur, Il Yong Chung, Jong Won Lee, Hyun Jo Youn, Se Jeong Oh, Cheol Wan Lim, Jihyoun Lee
    Journal of Breast Cancer.2021; 24(6): 561.     CrossRef
  • Meme Kanseri Cerrahisi Sonrası Lenfödem ve Uçak Seyahati
    Aysel GÜL, Dilek AYGİN
    İstanbul Gelişim Üniversitesi Sağlık Bilimleri Dergisi.2021; (15): 669.     CrossRef
  • Italian Men Tested for BRCA1/2 Mutation: Psychological Distress during 6-Month Follow-Up
    F. Pellini, S. Mirandola, E. Granuzzo, S. Urbani, G. Piccinni Leopardi, G. P. Pollini
    Journal of Oncology.2020; 2020: 1.     CrossRef
  • Comparing the Characteristics and Outcomes of Male and Female Breast Cancer Patients in Korea: Korea Central Cancer Registry
    Eun-Gyeong Lee, So-Youn Jung, Myong Cheol Lim, Jiwon Lim, Han-Sung Kang, Seeyoun Lee, Jai Hong Han, Heein Jo, Young-Joo Won, Eun Sook Lee
    Cancer Research and Treatment.2020; 52(3): 739.     CrossRef
  • The effect of chemotherapy on survival in patients with nonmetastatic male breast cancer: A population‐based observational study
    Hong Pan, Kai Zhang, Ming Wang, Lijun Ling, Shui Wang, Wenbin Zhou
    Cancer.2020; 126(S16): 3830.     CrossRef
  • Adjuvant Radiation Therapy for Male Breast Cancer—A Rare Indication?
    Tobias Forster, Clara Köhler, Rami El Shafie, Fabian Weykamp, Laila König, Nathalie Arians, Sebastian Adeberg, Laura Michel, Katharina Smetanay, Michael Golatta, Christof Sohn, Jörg Heil, Andreas Schneeweiss, Jürgen Debus, Juliane Hörner-Rieber
    Cancers.2020; 12(12): 3645.     CrossRef
  • Male Breast Cancer: Surgical and Genetic Features and a Multidisciplinary Management Strategy
    Francesca Pellini, Eleonora Granuzzo, Silvia Urbani, Sara Mirandola, Marina Caldana, Davide Lombardi, Elena Fiorio, Marta Mandarà, Giovanni Paolo Pollini
    Breast Care.2020; 15(1): 14.     CrossRef
  • Ultrasonographic and Mammographic Findings of Male Breast Disease
    Su Hong Kim, Young‐Seon Kim
    Journal of Ultrasound in Medicine.2019; 38(1): 243.     CrossRef
  • Pattern of care of adjuvant radiotherapy in male breast cancer patients in clinical practice: an observational study
    Paul Rogowski, Stephan Schönecker, Montserrat Pazos, Daniel Reitz, Michael Braun, Martin Pölcher, Claus Hanusch, Rachel Wuerstlein, Nadia Harbeck, Sven Mahner, Claus Belka, Stefanie Corradini
    Strahlentherapie und Onkologie.2019; 195(4): 289.     CrossRef
  • Survival analysis for male ductal and lobular breast cancer patients with different stages
    Jizhao Wang, Yuchen Sun, Jingkun Qu, Huang Zuo, Xixi Zhao, Lin Liu, Jinteng Feng, Jiansheng Wang, Guangjian Zhang
    Future Oncology.2019; 15(2): 167.     CrossRef
  • Clinical features of patients with male breast cancer in Shanxi province of China from 2007 to 2016
    Weigang Wang, Xiaoqin Xu, Baoguo Tian, Yan Wang, Lili Du, Ting Sun, Yanchun Shi, Xianwen Zhao, Yali Jia, Yanfeng Xi, Jiexian Jing
    Journal of Investigative Medicine.2019; 67(3): 699.     CrossRef
  • Metastasis pattern and prognosis of male breast cancer patients in US: a population-based study from SEER database
    Jun Xie, Yao-Yu Ying, Bin Xu, Yan Li, Xian Zhang, Chong Li
    Therapeutic Advances in Medical Oncology.2019;[Epub]     CrossRef
  • Different Patterns of Conditional Survival of Breast Cancer Patients by Age and Histologic Types: Evidence from the Korean Nationwide Registry
    So-Youn Jung, Kyu-Won Jung, Johyun Ha, Young-Joo Won, Young Ae Kim, Youngmee Kwon, Sun-Young Kong, Eun Sook Lee
    Cancer Epidemiology, Biomarkers & Prevention.2019; 28(7): 1169.     CrossRef
  • Diagnostic Value of Fine-Needle Aspiration in Male Breast Lesions
    Raza S. Hoda, Ronald N. Arpin III, Ravi V. Gottumukkala, Kevin S. Hughes, Amy Ly, Elena F. Brachtel
    Acta Cytologica.2019; 63(4): 319.     CrossRef
  • The endocrinology of male breast cancer
    Ian S Fentiman
    Endocrine-Related Cancer.2018; 25(6): R365.     CrossRef
  • Magee Equation Recurrence Score Is Associated With Distal Metastatic Risk in Male Breast Carcinomas
    Yanjun Hou, Harrison S Moosavi, Lai Wei, Anil V Parwani, Xiaoxian (Bill) Li, Zaibo Li
    American Journal of Clinical Pathology.2018; 150(6): 491.     CrossRef
  • Axillary lymph node metastasis as the first manifestation of male occult breast cancer
    Xinyu Wang, Liwen Fan, Wenxing Yan, Qi Zhang, Shunchao Bao, Ying Wang, Xin Bao, Linlin Liu
    Medicine.2018; 97(50): e13706.     CrossRef
  • A review of estrogen receptor/androgen receptor genomics in male breast cancer
    Tesa M Severson, Wilbert Zwart
    Endocrine-Related Cancer.2017; 24(3): R27.     CrossRef
  • Imaging the Male Breast
    Shruthi Ram, Shadi Aminololama-Shakeri
    Current Radiology Reports.2017;[Epub]     CrossRef
  • Mammary gland tumors in a male Cocker Spaniel
    Soon-Chan Kwon, Dae-Young Yoo, Minho Ko, Kwon-Young Lee, Ho-Hyun Kwak, In-Chul Park, In-Koo Hwang, Jung-Hoon Choi, Jin-Young Chung
    Acta Veterinaria Scandinavica.2017;[Epub]     CrossRef
  • Male occult breast cancer with axillary lymph node metastasis as the first manifestation
    Ruixin Xu, Jianbin Li, Yingjie Zhang, Hongbiao Jing, Youzhe Zhu
    Medicine.2017; 96(51): e9312.     CrossRef
  • 14,242 View
  • 249 Download
  • 36 Web of Science
  • 34 Crossref
Close layer
Adopting Advance Directives Reinforces Patient Participation in End-of-Life Care Discussion
Ji Hyung Hong, Jung Hye Kwon, Il Kyu Kim, Jin Hee Ko, Yi-Jin Kang, Hoon-Kyo Kim
Cancer Res Treat. 2016;48(2):753-758.   Published online October 14, 2015
DOI: https://doi.org/10.4143/crt.2015.281
AbstractAbstract PDFPubReaderePub
Purpose
In Korea, most terminal cancer patients have still not been included in end-of-life (EOL) discussions. The purpose of this study was to evaluate the proportion of patients participating in EOL discussions after adopting advance directives.
Materials and Methods
Medical records of 106 hospice patients between July 2012 and February 2013 were reviewed retrospectively. The proportion of patient participation in EOL discussions, barriers, and favorable factors for completion of advance directives, as well as outcomes of advance directives were evaluated.
Results
Patient participation in EOL discussion had increased from 16/53 (30%) to 27/53 (51%) since adopting advance directives (p < 0.001). Median time between completion of an advance directive and death increased from 8 days (range, 0 to 22 days) to 14.5 days (range, 0 to 47 days). Patients’ poor condition after late referral was the main barrier to missing EOL discussions; however, family members’ concerns about patient’s distress was also a main reason for excluding the patient from EOL discussions. In univariate analysis, patient age, education status, and time from diagnosis to completion of an advance directive influenced advance directive completion favorably. Following multivariate analysis, higher education and periods of more than 2 years from diagnosis to completion of an advance directive remained favorable (odds ratio [OR], 9.586, p=0.024 and OR, 70.312; p=0.002). Preferences of all patients regarding cardiopulmonary resuscitation or hemodialysis were carried out by physicians. Orders for nutrition and palliative sedation showed discordance, with concordance rates of 74.2% and 51.6%, respectively.
Conclusion
Our results suggested that the use of advance directive promote patient participation in EOL discussion.

Citations

Citations to this article as recorded by  
  • Participation and Influencing Factors in the Decision-Making of Life-Sustaining Treatment: A Focus on Deceased Patients with Hematologic Neoplasms
    Jae Eun Jang, Jeong Moon Ryu, Min Hee Heo, Do Eun Kwon, Ji Yeon Seo, Dong Yeon Kim
    The Korean Journal of Hospice and Palliative Care.2023; 26(2): 69.     CrossRef
  • Discussing POLST-facilitated hospice care enrollment in patients with terminal cancer
    Ho Jung An, Hyun Jeong Jeon, Sang Hoon Chun, Hyun Ae Jung, Hee Kyung Ahn, Kyung Hee Lee, Min-ho Kim, Ju Hee Kim, Jaekyung Cheon, Su-Jin Koh
    Supportive Care in Cancer.2022; 30(9): 7431.     CrossRef
  • A quantitative study of nurses perception to advance directive in selected private and public secondary healthcare facilities in Ibadan, Nigeria
    Oluwaseyi Emiola Ojedoyin, Ayodele Samuel Jegede
    BMC Medical Ethics.2022;[Epub]     CrossRef
  • Influence of advance directives on reducing aggressive measures during end-of-life cancer care: A systematic review
    Lillian Ponchio e Silva Marchi, Martins Fideles dos Santos Neto, Júlia de Pauli Moraes, Carlos Eduardo Paiva, Bianca Sakamoto Ribeiro Paiva
    Palliative and Supportive Care.2021; 19(3): 348.     CrossRef
  • A National Study of Life-Sustaining Treatments in South Korea: What Factors Affect Decision-Making?
    So-Youn Park, Bomyee Lee, Jeong Yeon Seon, In-Hwan Oh
    Cancer Research and Treatment.2021; 53(2): 593.     CrossRef
  • The Situation of Life-Sustaining Treatment One Year after Enforcement of the Act on Decisions on Life-Sustaining Treatment for Patients at the End-of-Life in Korea: Data of National Agency for Management of Life-Sustaining Treatment
    Ha Yeon Lee, Hwa Jung Kim, Jung Hye Kwon, Sun Kyung Baek, Young-Woong Won, Yu Jung Kim, Su Jin Baik, Hyewon Ryu
    Cancer Research and Treatment.2021; 53(4): 897.     CrossRef
  • Preparation and Practice of the Necessary Documents in Hospital for the “Act on Decision of Life-Sustaining Treatment for Patients at the End-of-Life”
    Sun Kyung Baek, Hwa Jung Kim, Jung Hye Kwon, Ha Yeon Lee, Young-Woong Won, Yu Jung Kim, Sujin Baik, Hyewon Ryu
    Cancer Research and Treatment.2021; 53(4): 926.     CrossRef
  • Modifiable Factors Associated with the Completion of Advance Treatment Directives in Hematologic Malignancy: A Patient–Caregiver Dyadic Analysis
    JinShil Kim, Jinny Park, Mee Ok Lee, Eun Young Park, Seongkum Heo, Jae Lan Shim
    Journal of Palliative Medicine.2020; 23(5): 611.     CrossRef
  • Nurses' perspectives on advance directives before the establishment of the new well-dying law in Korea: A mixed methods study
    Youn-Jung Son, JiYeon Choi, Jung-Won Ahn
    Applied Nursing Research.2020; 51: 151187.     CrossRef
  • Hospital Nurses’ Perception of Death and Self-Reported Performance of End-of-Life Care: Mediating Role of Attitude towards End-of-Life Care
    Hyo-Jin Park, Yun-Mi Lee, Mi Hwa Won, Sung-Jun Lim, Youn-Jung Son
    Healthcare.2020; 8(2): 142.     CrossRef
  • Implication of the Life-Sustaining Treatment Decisions Act on End-of-Life Care for Korean Terminal Patients
    Jung Sun Kim, Shin Hye Yoo, Wonho Choi, Yejin Kim, Jinui Hong, Min Sun Kim, Hye Yoon Park, Bhumsuk Keam, Dae Seog Heo
    Cancer Research and Treatment.2020; 52(3): 917.     CrossRef
  • Advance care planning in Asian culture
    Shao-Yi Cheng, Cheng-Pei Lin, Helen Yue-lai Chan, Diah Martina, Masanori Mori, Sun-Hyun Kim, Raymond Ng
    Japanese Journal of Clinical Oncology.2020; 50(9): 976.     CrossRef
  • Family Members' Experience of Discussions on End-of-Life Care in Nursing Homes in Japan
    Hiroki Kato, Keiko Tamura
    Journal of Hospice & Palliative Nursing.2020; 22(5): 401.     CrossRef
  • Efficacy of a Decision Aid Consisting of a Video and Booklet on Advance Care Planning for Advanced Cancer Patients: Randomized Controlled Trial
    Young Ho Yun, EunKyo Kang, Sohee Park, Su-Jin Koh, Ho-Suk Oh, Bhumsuk Keam, Young Rok Do, Won Jin Chang, Hyun Sik Jeong, Eun Mi Nam, Kyung Hae Jung, Hak Ro Kim, Jiyeon Choo, Jihye Lee, Jin-Ah Sim
    Journal of Pain and Symptom Management.2019; 58(6): 940.     CrossRef
  • Effect of the duration of hospice and palliative care on the quality of dying and death in patients with terminal cancer: A nationwide multicentre study
    J.Y. Choi, K.A. Kong, Y.J. Chang, H.J. Jho, E.M. Ahn, S.K. Choi, S. Park, M.K. Lee
    European Journal of Cancer Care.2018; 27(2): e12771.     CrossRef
  • End-of-Life Care and Discussions in Japanese Geriatric Health Service Facilities: A Nationwide Survey of Managing Directors’ Viewpoints
    Asako Kanoh, Yoshiyuki Kizawa, Satoru Tsuneto, Shoji Yokoya
    American Journal of Hospice and Palliative Medicine®.2018; 35(1): 83.     CrossRef
  • Does special education in palliative medicine make a difference in end-of-life decision-making?
    Reetta P. Piili, Juho T. Lehto, Tiina Luukkaala, Heikki Hinkka, Pirkko-Liisa I. Kellokumpu-Lehtinen
    BMC Palliative Care.2018;[Epub]     CrossRef
  • A Concept Analysis of End-of-life Discussions with Cancer Patients
    Midori Kadowaki
    Journal of Japan Academy of Nursing Science.2016; 36: 263.     CrossRef
  • 11,557 View
  • 144 Download
  • 16 Web of Science
  • 18 Crossref
Close layer
Case Report
Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid Leukemia
Ji Hyung Hong, Sung-Eun Lee, Soo Young Choi, Soo-Hyun Kim, Eun-Jung Jang, Ju-Hee Bang, Jin Eok Park, Hye-Rim Jeon, Yun Jeong Oh, Jeong-Eun Yi, Hae Ok Jung, Ho Joong Youn, Dong-Wook Kim
Cancer Res Treat. 2015;47(4):937-942.   Published online November 17, 2014
DOI: https://doi.org/10.4143/crt.2013.155
AbstractAbstract PDFPubReaderePub
We describe two cases of pulmonary arterial hypertension (PAH) that occurred under dasatinib treatment and were resolved after dasatinib discontinuation. Two patients with chronic phase chronic myeloid leukemia (CML) were switched to dasatinib therapy because of hematological progress while receiving imatinib. These patients had New York Heart Association (NYHA) functional class II dyspnea with elevated right ventricular systolic pressure (RVSP), which progressed under dasatinib treatment. After dasatinib treatment was discontinued, subjective symptoms were improved to NYHA functional class I and the follow-up transthoracic Doppler echocardiography showed improved RVSP. Treatment with an alternate tyrosine kinase inhibitor was initiated and had been continued without development of dyspnea or elevation of RVSP. This report suggests that dasatinib can cause the reversible PAH, therefore, routine cardiopulmonary evaluation before and during treatment with dasatinib may be needed in CML patients with clinical manifestations.

Citations

Citations to this article as recorded by  
  • Prevalence and predictors of pulmonary hypertension in patients with myeloproliferative neoplasms: single-center study
    Mohamed Eid, Ali M Kasem, Yasser M Kamal, Mahmoud Hamdy, Mahmoud Gaber
    The Egyptian Journal of Haematology.2024; 49(1): 45.     CrossRef
  • Relationship between Dasatinib-induced Pulmonary Hypertension and Drug Dose
    Kana Kubota, Yasushi Imai, Iekuni Oh, Shuichi Ueno, Yoshinobu Kanda, Kazuomi Kario
    Internal Medicine.2022; 61(15): 2263.     CrossRef
  • Change of right ventricular systolic pressure can indicate dasatinib‐induced pulmonary arterial hypertension in chronic myeloid leukemia
    Sung‐Eun Lee, Jee Hyun Kong, Soo‐Hyun Kim, Eun‐Jung Jang, Nack‐Gyun Chung, Bin Cho, Suk Joong Oh, Hae‐Eok Jung, Ho‐Joong Youn, Woo‐Baek Chung, Dong‐Wook Kim
    Cancer Medicine.2021; 10(5): 1515.     CrossRef
  • mTOR Signaling in Pulmonary Vascular Disease: Pathogenic Role and Therapeutic Target
    Aleksandra Babicheva, Ayako Makino, Jason X.-J. Yuan
    International Journal of Molecular Sciences.2021; 22(4): 2144.     CrossRef
  • Dasatinib-Induced Pulmonary Arterial Hypertension: A Case Report
    Ru Liu, Yinjiang Tang, Ting Fu, Jianli Zhou, Lijiao Ma, Jinqing Yuan, Ou Xu
    Research Reports in Clinical Cardiology.2021; Volume 12: 33.     CrossRef
  • Pulmonary hypertension in patients with chronic myeloid leukemia
    Ik-Chan Song, Sang-Hoon Yeon, Myeong-Won Lee, Hyewon Ryu, Hyo-Jin Lee, Hwan-Jung Yun, Byung Joo Sun, Jae-Hyeong Park, Jin-Ok Jeong, Deog-Yeon Jo
    Medicine.2021; 100(33): e26975.     CrossRef
  • A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities
    Zahra Nekoukar, Minoo Moghimi, Ebrahim Salehifar
    BLOOD RESEARCH.2021; 56(4): 229.     CrossRef
  • Dasatinib-induced pulmonary arterial hypertension complicated with scleroderma: a case report
    Takumi Toya, Yuji Nagatomo, Kazuki Kagami, Takeshi Adachi, Julia Grapsa, Julia Grapsa, Hatem Soliman Aboumarie, Amir Aziz, Peysh A Patel
    European Heart Journal - Case Reports.2019;[Epub]     CrossRef
  • Dasatinib‐induced pulmonary arterial hypertension
    Nurgül Özgür Yurttaş, Ahmet Emre Eşkazan
    British Journal of Clinical Pharmacology.2018; 84(5): 835.     CrossRef
  • Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib
    Mariko Minami, Takeshi Arita, Hiromi Iwasaki, Tsuyoshi Muta, Takatoshi Aoki, Kenichi Aoki, Satoshi Yamasaki, Takamitsu Matsushima, Koji Kato, Katsuto Takenaka, Kazuki Tanimoto, Tomohiko Kamimura, Ryosuke Ogawa, Koichi Akashi, Toshihiro Miyamoto
    British Journal of Haematology.2017; 177(4): 578.     CrossRef
  • Combination targeted pulmonary hypertension therapy in the resolution of Dasatinib‐associated pulmonary arterial hypertension
    Arun Jose, Hind Rafei, Jalil Ahari
    Pulmonary Circulation.2017; 7(4): 803.     CrossRef
  • Pulmonary arterial hypertension in a patient treated with dasatinib: a case report
    Andris Skride, Matiss Sablinskis, Kristaps Sablinskis, Krista Lesina, Aivars Lejnieks, Sandra Lejniece
    Journal of Medical Case Reports.2017;[Epub]     CrossRef
  • Pulmonary arterial hypertension in congenital heart disease: translational opportunities to study the reversibility of pulmonary vascular disease
    Diederik E. van der Feen, B. Bartelds, Rudolf A. de Boer, Rolf M.F. Berger
    European Heart Journal.2017; 38(26): 2034.     CrossRef
  • Dasatinib

    Reactions Weekly.2015; 1580(1): 136.     CrossRef
  • Deletion of Src family kinase Lyn aggravates endotoxin-induced lung inflammation
    Rong Gao, Zhongsen Ma, Mengshi Ma, Jinyan Yu, Jiao Chen, Zhenyu Li, Sreerama Shetty, Jian Fu
    American Journal of Physiology-Lung Cellular and Molecular Physiology.2015; 309(11): L1376.     CrossRef
  • 11,721 View
  • 136 Download
  • 18 Web of Science
  • 15 Crossref
Close layer
Original Article
Trends in the Aggressiveness of End-of-Life Care for Advanced Stomach Cancer Patients
Ji Hyung Hong, Sang-Young Rho, Young Seon Hong
Cancer Res Treat. 2013;45(4):270-275.   Published online December 31, 2013
DOI: https://doi.org/10.4143/crt.2013.45.4.270
AbstractAbstract PDFPubReaderePub
PURPOSE
It is important to balance the appropriateness of active cancer treatments and end-of-life care to improve the quality of life for terminally ill cancer patients. This study describes the treatment patterns and end-of-life care in terminal gastric cancer patients.
MATERIALS AND METHODS
We retrospectively analyzed the records of 137 patients with advanced gastric cancer receiving chemotherapy and dying between June 1, 2006 and May 31, 2011. We recorded interval between last chemotherapy dose and death; frequency of emergency room visits or admission to the intensive care unit in the last month before death; rate of hospice referral and agreement with written do-not-resuscitate orders; and change in laboratory values in the last three months before death.
RESULTS
During the last six months of life, 130 patients (94.9%) received palliative chemotherapy; 86 (62.7%) during the final two months; 41 (29.9%) during the final month. During the final month, 53 patients (38.7%) visited an emergency room more than once; 21 (15.3%) were admitted to the intensive care unit. Hospice referral occurred in 54% (74 patients) of the patients; 93.4% (128 patients) gave written do-not-resuscitate orders. Platelets, aspartate aminotransferase and creatinine changed significantly two weeks before death; total bilirubin, one month before; and C-reactive protein, between four and two weeks before death.
CONCLUSION
Our results demonstrated that a significant proportion of gastric cancer patients received palliative chemotherapy to the end of life and the patients who stopped the chemotherapy at least one month before death had a lower rate of intensive care unit admission and longer overall survival than those who sustained aggressive chemotherapy until the last months of their lives.

Citations

Citations to this article as recorded by  
  • Decreased aggressive care at the end of life among advanced cancer patients in the Republic of Korea: a nationwide study from 2012 to 2018
    Sara Kwon, Kyuwoong Kim, Bohyun Park, So-Jung Park, Hyun Jung Jho, Jin Young Choi
    BMC Palliative Care.2024;[Epub]     CrossRef
  • Automated machine learning (AutoML) can predict 90-day mortality after gastrectomy for cancer
    Gopika SenthilKumar, Sharadhi Madhusudhana, Madelyn Flitcroft, Salma Sheriff, Samih Thalji, Jennifer Merrill, Callisia N. Clarke, Ugwuji N. Maduekwe, Susan Tsai, Kathleen K. Christians, T. Clark Gamblin, Anai N. Kothari
    Scientific Reports.2023;[Epub]     CrossRef
  • A prospective cohort study assessing aggressive interventions at the end-of-life among patients with solid metastatic cancer
    Chetna Malhotra, Filipinas Bundoc, Isha Chaudhry, Irene Teo, Semra Ozdemir, Eric Finkelstein, Rebecca A. Dent, Nesaretnam Barr Kumarakulasinghe, Yin Bun Cheung, Rahul Malhotra, Ravindran Kanesvaran, Alethea Chung Pheng Yee, Noreen Chan, Huei Yaw Wu, Soh M
    BMC Palliative Care.2022;[Epub]     CrossRef
  • Quality of End-of-Life Care in Gastrointestinal Cancers: A 13-Year Population-Based Retrospective Analysis in Ontario, Canada
    Caitlin SR Lees, Hsien Seow, Kelvin KW Chan, Anastasia Gayowsky, Aynharan Sinnarajah
    Current Oncology.2022; 29(12): 9163.     CrossRef
  • Use of Palliative Chemotherapy and ICU Admissions in Gastric and Esophageal Cancer Patients in the Last Phase of Life: A Nationwide Observational Study
    Joost Besseling, Jan Reitsma, Judith A. Van Erkelens, Maike H. J. Schepens, Michiel P. C. Siroen, Cathelijne M. P. Ziedses des Plantes, Mark I. van Berge Henegouwen, Laurens V. Beerepoot, Theo Van Voorthuizen, Lia Van Zuylen, Rob H. A. Verhoeven, Hanneke
    Cancers.2021; 13(1): 145.     CrossRef
  • Efficacy of systemic oncological treatments in patients with advanced esophageal or gastric cancers at high risk of dying in the middle and short term: an overview of systematic reviews
    M. Santero, J. Pérez-Bracchiglione, R. Acosta-Dighero, A. G. Meade, A. Antequera, A. Auladell-Rispau, M. J. Quintana, C. Requeijo, G. Rodríguez-Grijalva, K. Salas-Gama, R. Dorantes-Romandia, J. Salazar, I. Solà, G. Urrútia, X. Bonfill Cosp
    BMC Cancer.2021;[Epub]     CrossRef
  • Health care utilization at end of life among patients with lung or pancreatic cancer. Comparison between two Swedish cohorts
    Helena Ullgren, Per Fransson, Anna Olofsson, Ralf Segersvärd, Lena Sharp, Amir Radfar
    PLOS ONE.2021; 16(7): e0254673.     CrossRef
  • Health care utilization among patients with oesophageal and gastric cancer: the impact of initial treatment strategy and assignment of a contact nurse
    Karin Dalhammar, Marlene Malmström, Magnus Sandberg, Dan Falkenback, Jimmie Kristensson
    BMC Health Services Research.2021;[Epub]     CrossRef
  • Conceptualizing and Counting Discretionary Utilization in the Final 100 Days of Life: A Scoping Review
    Paul R. Duberstein, Michael Chen, Michael Hoerger, Ronald M. Epstein, Laura M. Perry, Sule Yilmaz, Fahad Saeed, Supriya G. Mohile, Sally A. Norton
    Journal of Pain and Symptom Management.2020; 59(4): 894.     CrossRef
  • The impact of initial treatment strategy and survival time on quality of end-of-life care among patients with oesophageal and gastric cancer: A population-based cohort study
    Karin Dalhammar, Marlene Malmström, Maria Schelin, Dan Falkenback, Jimmie Kristensson, Jason Chia-Hsun Hsieh
    PLOS ONE.2020; 15(6): e0235045.     CrossRef
  • Outpatient Palliative Care and Aggressiveness of End-of-Life Care in Patients with Metastatic Colorectal Cancer
    Si Won Lee, Hyun Jung Jho, Ji Yeon Baek, Eun Kyung Shim, Hyun Mi Kim, Ji Yeon Ku, Eun Jung Nam, Yoon-Jung Chang, Hye Jin Choi, Sun Young Kim
    American Journal of Hospice and Palliative Medicine®.2018; 35(1): 166.     CrossRef
  • Patterns and Yearly Time Trends in the Use of Radiation Therapy During the Last 30 Days of Life Among Patients With Metastatic Rectal Cancer in the United States From 2004 to 2012
    Adan Z. Becerra, Christian P. Probst, Fergal J. Fleming, Zhaomin Xu, Christopher T. Aquina, Carla F. Justiniano, Courtney I. Boodry, Alex A. Swanger, Katia Noyes, Alan W. Katz, John R. Monson, Todd A. Jusko
    American Journal of Hospice and Palliative Medicine®.2018; 35(2): 336.     CrossRef
  • Decreasing mortality and hospitalizations with rising costs related to gastric cancer in the USA: an epidemiological perspective
    Delong Liu, Dhruv Mehta, Supreet Kaur, Arun Kumar, Kaushal Parikh, Lavneet Chawla, Shanti Patel, Amirta Devi, Aparna Saha
    Journal of Hematology & Oncology.2018;[Epub]     CrossRef
  • Frequency and Predictors of Acute Hospitalization Before Death in Patients With Glioblastoma
    Eli L. Diamond, Katherine S. Panageas, Alexis Dallara, Ariel Pollock, Allison J. Applebaum, Alan C. Carver, Elena Pentsova, Lisa M. DeAngelis, Holly G. Prigerson
    Journal of Pain and Symptom Management.2017; 53(2): 257.     CrossRef
  • The effects of hospice-shared care for gastric cancer patients
    Kun-Siang Huang, Shih-Ho Wang, Seng-Kee Chuah, Kun-Ming Rau, Yu-Hung Lin, Meng-Che Hsieh, Li-Hsueh Shih, Yen-Hao Chen, Ramon Andrade de Mello
    PLOS ONE.2017; 12(2): e0171365.     CrossRef
  • Clinical significance and predicting indicators of post‐cancer‐treatment survival in terminally ill patients with ovarian cancer
    Fumi Utsumi, Hiroaki Kajiyama, Kaoru Niimi, Ryuichiro Sekiya, Jun Sakata, Shiro Suzuki, Kiyosumi Shibata, Mika Mizuno, Fumitaka Kikkawa
    Journal of Obstetrics and Gynaecology Research.2017; 43(2): 365.     CrossRef
  • Adopting Advance Directives Reinforces Patient Participation in End-of-Life Care Discussion
    Ji Hyung Hong, Jung Hye Kwon, Il Kyu Kim, Jin Hee Ko, Yi-Jin Kang, Hoon-Kyo Kim
    Cancer Research and Treatment.2016; 48(2): 753.     CrossRef
  • Cases and Literature Review of Timing for Withdrawal of Palliative Chemotherapy
    Yun Jin Jeong, Do Yeun Kim
    The Korean Journal of Hospice and Palliative Care.2016; 19(1): 70.     CrossRef
  • End-of-life care for hospitalized patients with metastatic melanoma in France: a nationwide, register-based study
    I. Gallais Sérézal, Y. Beaussant, P. Rochigneux, C. Tournigand, R. Aubry, B. Lindelöf, L. Morin
    British Journal of Dermatology.2016; 175(3): 583.     CrossRef
  • Trends in the Aggressiveness of End-of-Life Cancer Care in the State of Qatar
    Azza A. Hassan, Hassan Mohsen, Ayman A. Allam, Pascale Haddad
    Journal of Global Oncology.2016; 2(2): 68.     CrossRef
  • Investigational tests and treatments performed in terminal stage cancer patients in two weeks before death: Turkish oncology group (TOG) study
    İbrahim Türker, Şeref Kömürcü, Ali Arıcan, Hatice Doruk, Özgür Özyılkan, Hasan Şenol Coşkun, Dilşen Çolak, Emel Üçgül Çavuşoğlu, Alper Ata, Ahmet Sezer, Havva Yeşil Çınkır, Filiz Çay Şenler, Fikret Arpacı
    Medical Oncology.2014;[Epub]     CrossRef
  • 11,891 View
  • 82 Download
  • 21 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP